Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 7Carcinoma, Renal Cell 4Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Medullary 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Pheochromocytoma 2Paraganglioma 2Osteosarcoma 2Neurofibroma, Plexiform 2Glioma 2Astrocytoma 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdoid Tumor 1Paraganglioma, Extra-Adrenal 1Neurofibromatosis 1 1Neurofibromatoses 1Neuroendocrine Tumors 1Neuroblastoma 1Meningioma 1Melanoma 1Lung Neoplasms 1Hepatoblastoma 1

Interventions

trametinib 2dabrafenib 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1sargramostim 1cobimetinib 1cabozantinib 1atezolizumab 1aldesleukin 1Vemurafenib 1Trastuzumab 1Tamoxifen 1Semaxinib 1Radiotherapy 1Paclitaxel 1Gefitinib 1Doxorubicin 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × cabozantinib × CNS × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡